"The failure of Proleukin (Interleukin-2, IL-2) to demonstrate a clinical benefit in the SILCAAT and ESPRIT studies earlier this year might have resulted because the drug increased immune system inflammation, according to an article published October 15 in The New England Journal of Medicine (NEJM)."
Read more in POZ, October 15, 2009.
0 comments:
Post a Comment